Batavia Biosciences releases ‘Amalia,’ a novel manufacturing facility in Leiden, The Netherlands, enhancing their capability in viral vaccine and vector production.
Batavia Biosciences has announced the launch of ‘Amalia,’ a new GMP-ready manufacturing facility in Bilthoven, Netherlands.
This facility marks a significant advancement in the company’s ability to produce viral vaccines and viral vectors for clinical manufacturing. Menzo Havenga, CEO of Batavia Biosciences, highlights that Amalia aligns with the company’s mission to bring medical solutions from the lab to patients, especially in the context of epidemic preparedness.
The facility, equipped with advanced technology and adhering to high-quality standards, is set to play a crucial role in vaccine and viral vector development and production.
Amalia is part of Batavia Biosciences’ broader expansion strategy, with further developments anticipated, including a larger facility in Leiden.
For more details and future updates from Batavia Biosciences, please refer to their official announcements.
Leiden Bio Science Park welcomed a high-level Shanghai delegation, led by Vice Mayor Liu Duo, marking a key step toward international collaboration in life sciences. The visit, initiated by Shanghai, showcased mutual interest in innovation and partnership.
The Netherlands will host the NATO Summit on 24-25 June 2025 at the World Forum in The Hague, leading to significant traffic disruptions and security measures across the Randstad region from 22-26 June. Motorists can expect road closures on major routes, while public transport services will be adjusted, with certain trams and buses suspended, and travelers are advised to avoid the area or use alternative transportation options.
This summer, students and professionals passionate about pharmaceutical innovation have a unique opportunity to gain hands-on experience in modern drug development. The...